Iodine increases pulmonary type I interferon responses and decreases covid-19 disease severity: Results from an open label randomized clinical trial

These findings suggest that while iodine does not reduce mortality or ICU admissions, it may enhance antiviral immunity through increased type I interferon responses, contributing to shorter ICU stays in COVID-19 patients. The role of iodine in enhancing IFN-I mediated antiviral immunity warrants future research. Registration of trial: EudraCT Number: 2020-001852-16. https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001852-16 Sponsor name: Maxima Medical Center. Date of Registration: April 1st 2020.